Liver/Biliary Disorders News

Elafibranor sustained biochemical response through week 78 in patients with primary biliary cholangitis and has a “potential beneficial effect” on itch-related quality of life, according to late-breaking data presented at EASL Congress.

Recurrence of hepatic encephalopathy was lower among patients with cirrhosis and hepatic encephalopathy who received oral capsule or enema fecal microbiota transplant vs. placebo, according to research from EASL Congress.

WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported.

BOSTON — Accumulating sedentary time during childhood was associated with increased risk for liver disease in young adulthood, but boosting light physical activity may lessen the risk, according to data presented at ENDO 2024.

WASHINGTON — Researchers have determined that several noninvasive tests could help identify candidates for treatment with Rezdiffra, as well as predict response, in metabolic dysfunction-associated steatohepatitis.

Sinusoidal obstructive syndrome is a rare but potentially serious complication that can occur after hematopoietic stem cell transplantation.

WASHINGTON — Survodutide sustained improvement in liver fat content, liver enzymes and fibrosis biomarkers in patients with metabolic dysfunction-associated steatohepatitis at 28 weeks, according to a late-breaking abstract presented here.

WASHINGTON — The risk for advanced fibrosis was similar among patients with lean and non-lean metabolic dysfunction-associated steatotic liver disease and may be associated with genetic risk, according to data at Digestive Disease Week.

The FDA has granted breakthrough therapy designation to Durect’s larsucosterol for the treatment of patients with severe alcohol-associated hepatitis, despite mixed results from previously released topline data.

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.